Zobrazeno 1 - 4
of 4
pro vyhledávání: '"José R. W. Martínez"'
Autor:
José R. W. Martínez, Paul J. Planet, Maria Spencer-Sandino, Lina Rivas, Lorena Díaz, Ahmed M. Moustafa, Ana Quesille-Villalobos, Roberto Riquelme-Neira, Manuel Alcalde-Rico, Blake Hanson, Lina P. Carvajal, Sandra Rincón, Jinnethe Reyes, Marusella Lam, Juan F. Calderon, Rafael Araos, Patricia García, César A. Arias, José M. Munita
Publikováno v:
Microbiology Spectrum, Vol 11, Iss 4 (2023)
ABSTRACT The global dissemination of methicillin-resistant Staphylococcus aureus (MRSA) is associated with the emergence and establishment of clones in specific geographic areas. The Chilean-Cordobes clone (ChC) (ST5-SCCmecI) has been the predominant
Externí odkaz:
https://doaj.org/article/f55e93ea59644a27804b9496192374f1
Autor:
María F. Mojica, Elsa De La Cadena, Rafael Ríos, Juan Carlos García-Betancur, Lorena Díaz, Jinnethe Reyes, Cristhian Hernández-Gómez, Marcela Radice, Ana C. Gales, Paulo Castañeda Méndez, José M. Munita, Christian José Pallares, José R. W. Martínez, María Virginia Villegas
Publikováno v:
Frontiers in Microbiology, Vol 13 (2022)
ObjectivesIdentify molecular mechanisms responsible for the in vitro non-susceptibility to ceftolozane/tazobactam (TOL) in a group of 158 clinical isolates of Pseudomonas aeruginosa from five Latin American countries collected before the introduction
Externí odkaz:
https://doaj.org/article/bad2ea52247c4e068b84db4d0044bbb6
Autor:
María José Contreras-Gómez, José R. W. Martinez, Lina Rivas, Roberto Riquelme-Neira, Juan A. Ugalde, Aniela Wozniak, Patricia García, José M. Munita, Jorge Olivares-Pacheco, Manuel Alcalde-Rico
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is one of the pathogens that urgently needs new drugs and new alternatives for its control. The primary strategy to combat this bacterium is combining treatments of beta-lactam with a beta-lactamase
Externí odkaz:
https://doaj.org/article/795fda49ba254963af836aec16c223d9
Autor:
Patricia García, Bárbara Brito, Manuel Alcalde-Rico, José M. Munita, Jose R. W. Martínez, Jorge Olivares-Pacheco, Valeria Quiroz, Aniela Wozniak
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 12 (2022)
Ceftazidime/Avibactam (CAZ/AVI) is frequently used to treat KPC-producing Pseudomonas aeruginosa (KPC-PA) and Enterobacterales. CAZ/AVI resistance is driven by several mechanisms. In P. aeruginosa this mainly occurs through alteration of AmpC, porins
Externí odkaz:
https://doaj.org/article/fea74c6918674e4081a5ba9a11fdf48d